TRENTON, N.J. (AP) — A generic drugmaker plans to start selling a slightly cheaper version of the EpiPen in the U.S. early next year.
The penlike injectors are used to treat life-threatening allergic reactions. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.
Drugmaker Sandoz said Thursday the price of two generic injectors will be $250 without insurance. Two other generics on the market in the U.S. cost $300 a pair. Brand-name EpiPens sold by Mylan cost at least twice as much.
The price people pay varies, though, depending on insurance and discounts.
Mylan was blasted in the past for price hikes that pushed the price over $600. It responded by selling its own generic.
- Drugmaker to sell cheaper generic rival to EpiPen injectors
- Illinois just became the first state to require insurance companies to cover EpiPen injectors for kids
- US approves new generic competitor to EpiPen
- Lilly to sell cheaper version of top-selling insulin Humalog
- FDA anticipates EpiPen shortage
- Malfunctioning EpiPens could harm patients, companies say
- Drugmaker halts shipments of ranitidine heartburn medication after contaminant found
- FDA extends some EpiPen expiration dates due to shortage
- Cashing in on dementia patients: drugmaker to pay $116 million in fraud settlement
- Illinois to become first state to require insurance companies to cover cost of EpiPEns for kids